Influx Healthtech Ltd
Influx Healthtech Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #35 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Influx Healthtech Ltd Q4 FY26 key numbers
- Revenue
- The company anticipates steady capacity utilization growth, with new plants expected to be operational around August, contributing approximately INR 40-50 crores in H2 FY '27.
As stated in Influx Healthtech Ltd's Q4 FY26 earnings call transcript · published 28 May 2026. Reported figures, not investment advice.
The short version
Influx Healthtech targets a minimum growth of 25% to 30% in FY '27, with ambitions to surpass this range, potentially reaching 35% to 40% based on past achievements. The company expects a minimum growth of 25% to 30% in revenue for FY '27, with potential to exceed up to 35%-40% based on past performance.
From Influx Healthtech Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Influx Healthtech targets a minimum growth of 25% to 30% in FY '27, with ambitions to surpass this range, potentially reaching 35% to 40% based on past achievements.
- The company anticipates steady capacity utilization growth, with new plants expected to be operational around August, contributing approximately INR 40-50 crores in H2 FY '27.
- The veterinary segment and pet care market are expected to grow significantly, with capacity increasing from 150 kg/hour to around 1000 kg/hour (an 8x increase), gradually improving margins.
- Export revenues currently contribute around 15-20%, with an expected annual increase of 5-7% in export quantum.
2 more points from Influx Healthtech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Influx Healthtech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- INR 13.84 crores of IPO proceeds allocated for capex utilized as of March 31, 2026.
- Board approved reallocation of INR 10 crores from veterinary, home care, and cosmetic divisions to expand nutraceutical CDMO facility.
- New facility (~75,000 sq. ft.) commissioning expected by July/August 2026, capacity to be 2.5x existing, targeting INR 450-500 crores revenue in a few years.
- Installed a new granulation line with ~480 kg/day capacity (24,000 bottles/day).
- Protein/snack bar segment growing strongly; pet food extrusion line ordered, capacity increasing from 100-150 kg/hr to 1000 kg/hr.
- Beverage segment building a canning facility and carbonated line; includes Tetra pack line booked.
- Investment in innovative packaging machinery (e.g., for cosmetics) imported.
2 more points from Influx Healthtech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Influx Healthtech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company does not have long-term contracts typical in the industry, with some clients providing projections for 3 months to 1 year (e.g., Octavius has given a 1-year plan, Novus a 3-month projection).
- Existing clients are growing steadily and contributing to the order book; the top 50-100 clients remain largely the same.
- The new facility, equipped with more automated lines, is expected to serve larger clients, while the current facility will cater to medium and small clients.
- Capacity utilization is expected to build slowly and steadily; filling the new capacity will take time and is not expected immediately.
- The company anticipates regular growth of 25-30% year-on-year, inclusive of contributions from the new facility.
2 more points from Influx Healthtech Ltd's call on order book
Create a free account to keep reading this call
What the Q4 FY26 call signalled
3 of 5 strong
Continue your research
What Influx Health.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Influx Healthtech Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Influx Healthtech Ltd Q4 FY26 results?
Influx Healthtech targets a minimum growth of 25% to 30% in FY '27, with ambitions to surpass this range, potentially reaching 35% to 40% based on past achievements. The company expects a minimum growth of 25% to 30% in revenue for FY '27, with potential to exceed up to 35%-40% based on past performance.
What is Influx Healthtech Ltd share price analysis?
Influx Healthtech Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 33.5 with a market cap of ₹689 Cr. Investors should review the full earnings analysis for detailed insights.
Is Influx Healthtech Ltd planning capital expenditure?
INR 13.84 crores of IPO proceeds allocated for capex utilized as of March 31, 2026. - Board approved reallocation of INR 10 crores from veterinary, home care, and cosmetic divisions to expand nutraceutical CDMO facility. - New facility (~75,000 sq.
Keep Influx Healthtech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.